Torrent Pharmaceuticals Ltd
TORNTPHARMTorrent Pharmaceuticals Ltd
TORNTPHARM
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 67.76 | 17.15 | 0.81% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.22 | 6.55 | 0.48% |
Forecast & Ratings
Detailed Forecast from 29 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Torrent Pharmaceuticals Limited is engaged in the manufacture and sale of branded, as well as unbranded generic pharmaceutical products.
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,912.50 | 6,038.99 | 6,248.67 | 7,729.85 | 8,060.61 | 8,061.48 | 8,704.60 | 9,665.29 | 10,874.13 | 11,132.00 | ||||||||||
Raw Materials | 1,725.04 | 1,931.39 | 2,035.67 | 2,136.25 | 2,300.05 | 2,425.66 | 2,368.15 | 2,569.00 | 2,841.22 | 7,515.00 | ||||||||||
| Power & Fuel Cost | 92.59 | 107.98 | 118.77 | 132.46 | 128.19 | 122.94 | 144.19 | 155.28 | 145.20 | |||||||||||
| Employee Cost | 842.35 | 993.41 | 1,135.25 | 1,403.79 | 1,429.04 | 1,439.62 | 1,526.45 | 1,677.69 | 1,984.40 | |||||||||||
| Selling & Administrative Expenses | 847.92 | 964.14 | 1,084.65 | 1,299.49 | 1,317.15 | 1,155.10 | 1,278.57 | 1,502.70 | 1,674.65 | |||||||||||
| Operating & Other expenses | 639.63 | 441.50 | 226.24 | 1,074.76 | 594.52 | 381.17 | 1,244.11 | 873.43 | 714.72 | |||||||||||
EBITDA | 2,764.97 | 1,600.57 | 1,648.09 | 1,683.10 | 2,291.66 | 2,536.99 | 2,143.13 | 2,887.19 | 3,513.94 | 3,617.00 | ||||||||||
| Depreciation/Amortization | 237.55 | 306.92 | 408.60 | 617.69 | 654.38 | 657.79 | 662.16 | 706.59 | 808.27 | 814.00 | ||||||||||
| PBIT | 2,527.42 | 1,293.65 | 1,239.49 | 1,065.41 | 1,637.28 | 1,879.20 | 1,480.97 | 2,180.60 | 2,705.67 | 2,803.00 | ||||||||||
| Interest & Other Items | 183.98 | 205.56 | 308.48 | 503.75 | 450.71 | 352.94 | 255.06 | 333.44 | 353.56 | 326.00 | ||||||||||
| PBT | 2,343.44 | 1,088.09 | 931.01 | 561.66 | 1,186.57 | 1,526.26 | 1,225.91 | 1,847.16 | 2,352.11 | 2,477.00 | ||||||||||
| Taxes & Other Items | 610.20 | 154.54 | 252.90 | 125.38 | 161.85 | 274.38 | 448.73 | 601.93 | 695.73 | 742.00 | ||||||||||
| Net Income | 1,733.24 | 933.55 | 678.11 | 436.28 | 1,024.72 | 1,251.88 | 777.18 | 1,245.23 | 1,656.38 | 1,735.00 | ||||||||||
| EPS | 51.21 | 27.58 | 20.03 | 12.89 | 30.28 | 36.99 | 22.96 | 36.79 | 48.94 | 51.26 | ||||||||||
| DPS | 17.50 | 7.00 | 7.00 | 8.50 | 16.00 | 17.50 | 24.00 | 22.00 | 28.00 | 28.00 | ||||||||||
| Payout ratio | 0.34 | 0.25 | 0.35 | 0.66 | 0.53 | 0.47 | 1.05 | 0.60 | 0.57 | 0.55 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Torrent Pharmaceuticals Ltd | 70.97 | 17.15 | 0.81% |
| Sun Pharmaceutical Industries Ltd | 47.86 | 6.83 | 0.71% |
| Cipla Ltd | 31.81 | 4.89 | 0.80% |
| Dr Reddy's Laboratories Ltd | 19.81 | 3.91 | 0.60% |
Price Comparison
Compare TORNTPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Torrent Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Kotak Emerging Equity Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4685% | Percentage of the fund’s portfolio invested in the stock 1.07% | Change in the portfolio weight of the stock over the last 3 months -0.24% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 40/71 (-6) |
UTI Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2607% | Percentage of the fund’s portfolio invested in the stock 1.11% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/70 (0) |
Nippon India Pharma Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1492% | Percentage of the fund’s portfolio invested in the stock 2.03% | Change in the portfolio weight of the stock over the last 3 months -0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/36 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
TORNTPHARM has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.83%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.29 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 21, 2024
Dividend/Share
₹6.00
Ex DateEx Date
Jun 21, 2024
Cash Dividend
Ex DateEx DateFeb 12, 2024
Dividend/Share
₹22.00
Ex DateEx Date
Feb 12, 2024
Cash Dividend
Ex DateEx DateJun 23, 2023
Dividend/Share
₹8.00
Ex DateEx Date
Jun 23, 2023
Cash Dividend
Ex DateEx DateFeb 3, 2023
Dividend/Share
₹14.00
Ex DateEx Date
Feb 3, 2023
Cash Dividend
Ex DateEx DateJun 3, 2022
Dividend/Share
₹15.00
Ex DateEx Date
Jun 3, 2022
Torrent Pharmaceuticals announced that Pranav Mehta has been elevated as Executive Director from Vice President of the company with effect from 01 April 2024. Powered by Capital Market - Live
Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%
Torrent Pharmaceuticals set to acquire KKR’s stake in JB Chemicals
Torrent Pharma Q1 Results Review- Segment Continues To Drive Growth: Centrum
Stocks in news: HUL, Vedanta, DRL, L&T, Axis Bank, Torrent Pharma and Titagarh Rail
Torrent Pharma tanks 4% post Q1FY25 results; analysts update target prices
Torrent Pharma Q1FY25 results: Net profit up 21%, revenue rises 10%
Hot stocks: Brokerage view on HUL, Zensar Tech, Kajaria Ceramics, Torrent Pharma, ICICI Pru and Bajaj Finance
Stock Alert: Bajaj Finance, Hindustan Unilever, Torrent Pharma, Schaeffler India, ICICI Securities,
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 7.06%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 3.52% to 2.88%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 30.58%, vs industry avg of 15.28%